Technical Analysis for ZLAB - Zai Lab Limited
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 15.91 | 1.08% | 0.17 |
ZLAB closed up 1.08 percent on Friday, April 26, 2024, on 63 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: May 8
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| Weak + Overbought | Other | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Up 5 Days in a Row | Strength | 0.00% | |
| New Downtrend | Bearish | 1.08% | |
| 20 DMA Support | Bullish | 1.08% | |
| Up 3 Days in a Row | Strength | 1.08% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 7 hours ago |
| Up 1% | about 7 hours ago |
| 20 DMA Support | 1 day ago |
| Down 3% | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2024
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Natural Sciences Infectious Diseases Medication Chemical Substances Autoimmune And Infectious Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Natural Sciences Infectious Diseases Medication Chemical Substances Autoimmune And Infectious Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 39.5 |
| 52 Week Low | 13.48 |
| Average Volume | 576,430 |
| 200-Day Moving Average | 23.65 |
| 50-Day Moving Average | 17.53 |
| 20-Day Moving Average | 15.20 |
| 10-Day Moving Average | 14.81 |
| Average True Range | 0.77 |
| RSI (14) | 50.00 |
| ADX | 24.08 |
| +DI | 24.18 |
| -DI | 25.07 |
| Chandelier Exit (Long, 3 ATRs) | 14.44 |
| Chandelier Exit (Short, 3 ATRs) | 15.78 |
| Upper Bollinger Bands | 16.77 |
| Lower Bollinger Band | 13.62 |
| Percent B (%b) | 0.73 |
| BandWidth | 20.72 |
| MACD Line | -0.61 |
| MACD Signal Line | -0.92 |
| MACD Histogram | 0.3174 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.47 | ||||
| Resistance 3 (R3) | 16.45 | 16.25 | 16.37 | ||
| Resistance 2 (R2) | 16.25 | 16.11 | 16.26 | 16.34 | |
| Resistance 1 (R1) | 16.08 | 16.02 | 16.17 | 16.10 | 16.31 |
| Pivot Point | 15.88 | 15.88 | 15.92 | 15.89 | 15.88 |
| Support 1 (S1) | 15.71 | 15.74 | 15.80 | 15.73 | 15.51 |
| Support 2 (S2) | 15.51 | 15.65 | 15.52 | 15.48 | |
| Support 3 (S3) | 15.34 | 15.51 | 15.45 | ||
| Support 4 (S4) | 15.36 |
